Carcinogenesis, Teratogenesis & Mutagenesis ›› 2024, Vol. 36 ›› Issue (4): 315-319.doi: 10.3969/j.issn.1004-616x.2024.04.012
Received:2023-01-09
Revised:2023-10-08
Published:2024-08-06
CLC Number:
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] LIANG J, GUAN X, BAO G, et al. Molecular subtyping of small cell lung cancer[J]. Semin Cancer Biol, 2022, 86(pt 2): 450-462. [2] A plan of attack for deadly cancers[J]. Cancer Discov, 2014, 4(9): 980. [3] TARIQ S, KIM S Y, MONTEIRO DE OLIVEIRA NOVAES J, et al. Update 2021: management of small cell lung cancer[J]. Lung, 2021, 199(6): 579-587. [4] SIMPSON K L, STONEY R, FRESE K K, et al. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity[J]. Nat Cancer, 2020, 1(4): 437-451. [5] DRAPKIN B J, GEORGE J, CHRISTENSEN C L, et al. Genomic and functional fidelity of small cell lung cancer patient-derived xenografts [J]. Cancer Discov, 2018, 8(5): 600-615. [6] STEWART C A, GAY C M, XI Y X, et al. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer[J]. Nat Cancer, 2020, 1: 423-436. [7] RUDIN C M, BRAMBILLA E, FAIVRE-FINN C, et al. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3. [8] RUDIN C M, POIRIER J T, BYERS L A, et al. Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data[J]. Nat Rev Cancer, 2019, 19(5): 289-297. [9] GAZDAR A F, SAVAGE T K, JOHNSON J E, et al. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung[J]. J Thorac Oncol, 2015, 10(4): 553-564. [10] CHOI S Y, CHO Y H, KIM D S, et al. Establishment and long-term expansion of small cell lung cancer patient-derived tumor organoids[J]. Int J Mol Sci, 2021, 22(3): 1349. [11] PASTUSHENKO I, BLANPAIN C. EMT transition states during tumor progression and metastasis[J]. Trends Cell Biol, 2019, 29(3): 212-226. [12] WANG Y, LIU Y X, ZHANG L N, et al. Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer[J]. J Cancer Res Clin Oncol, 2019, 145(12): 2911-2920. [13] XU J F, LIU S L, YANG X P, et al. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/ PI3K/Akt signaling in pancreatic cancer in vitro[J]. Life Sci, 2020, 263: 118523. [14] HUANG J L, CAO D D, SHA J, et al. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer[J]. Biochem Biophys Res Commun, 2019, 514(3): 853-860. [15] MESSARITAKIS I, NIKOLAOU M, KOINIS F, et al. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment[J]. Lung Cancer, 2019, 135: 33-39. [16] FURUTA M, KIKUCHI H, SHOJI T, et al. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail[J]. Cancer Sci, 2019, 110(5): 1599-1608. [17] 周菁, 郭丽. DLL3沉默抑制小细胞肺癌细胞系H592的增殖和迁移[J]. 江苏大学学报: 医学版, 2020, 30(4): 330-335. [18] GIFFIN M J, COOKE K, LOBENHOFER E K, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer[J]. Clin Cancer Res, 2021, 27(5): 1526-1537. [19] SONG J M, IM J, NHO R S, et al. Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells [J]. Mol Carcinog, 2019, 58(3): 321-333. [20] WANG Y, GUO Y, LIN H F, et al. Expression of CD44 in tumor tissue and serum of small cell lung cancer and its clinical prognostic significance[J]. Chin J Lung Cancer, 2021, 24(8): 583-590. [21] ZHAO C, ZHANG Z Y, HU X S, et al. Hyaluronic acid correlates with bone metastasis and predicts poor prognosis in small-cell lung cancer patients[J]. Front Endocrinol, 2021, 12: 785192. [22] JIN Y J, ZHAO Q Q, ZHU W K, et al. Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis[J]. Natl Sci Rev, 2022, 9(7): nwab232. [23] ILHAN-MUTLU A, SIEHS C, BERGHOFF A S, et al. Expression profiling of angiogenesis-related genes in brain metastases of lung cancer and melanoma[J]. Tumour Biol, 2016, 37(1): 1173-1182. [24] LI B, WANG C, ZHANG Y, et al. Elevated PLGF contributes to smallcell lung cancer brain metastasis[J]. Oncogene, 2013, 32(24): 2952- 2962. [25] KWON M C, PROOST N, SONG J Y, et al. Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis[J]. Genes Dev, 2015, 29(15): 1587- 1592. [26] DENNY S K, YANG D, CHUANG C H, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility[J]. Cell, 2016, 166(2): 328-342. [27] SEMENOVA E A, KWON M C, MONKHORST K, et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients[J]. Cell Rep, 2016, 16(3): 631-643. [28] WU N, JIA D S, IBRAHIM A H, et al. NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer[J]. Oncotarget, 2016, 7(36): 57514-57524. [29] YANG D, QU F F, CAI H C, et al. Axon-like protrusions promote small cell lung cancer migration and metastasis[J]. Elife, 2019, 8: e50616. [30] LIU C N, YI J H, JIA J M. Diagnostic and prognostic nomograms for bone metastasis in small cell lung cancer[J]. J Int Med Res, 2021, 49(10): 3000605211050735. [31] BÖTTGER F, SEMENOVA E A, SONG J Y, et al. Tumor heterogeneity underlies differential cisplatin sensitivity in mouse models of small-cell lung cancer[J]. Cell Rep, 2019, 27(11): 3345-3358.e4. [32] HOU J M, KREBS M G, LANCASHIRE L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer[J]. J Clin Oncol, 2012, 30(5): 525-532. [33] LIM J S, IBASETA A, FISCHER M M, et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer[J]. Nature, 2017, 545(7654): 360-364. [34] BEST S A, HESS J B, SOUZA-FONSECA-GUIMARAES F, et al. Harnessing natural killer immunity in metastatic SCLC[J]. J Thorac Oncol, 2020, 15(9): 1507-1521. [35] SIONOV R V, FRIDLENDER Z G, GRANOT Z. The multifaceted roles neutrophils play in the tumor microenvironment[J]. Cancer Microenviron, 2015, 8(3): 125-158. [36] SZCZERBA B M, CASTRO-GINER F, VETTER M, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression[J]. Nature, 2019, 566(7745): 553-557. [37] ZHU H H, LIU Y T, FENG Y, et al. Circulating tumor cells (CTCs)/ circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis[J]. Thorac Cancer, 2021, 12(20): 2749-2757. [38] WILLIAMSON S C, METCALF R L, TRAPANI F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun, 2016, 7: 13322. [39] HEIDEMANN F, SCHILDT A, SCHMID K, et al. Selectins mediate small cell lung cancer systemic metastasis[J]. PLoS One, 2014, 9(4): e92327. [40] ZHAO G X, GONG L Y, SU D, et al. Cullin5 deficiency promotes smallcell lung cancer metastasis by stabilizing integrin β1[J]. J Clin Invest, 2019, 129(3): 972-987. [41] MA N Q, PANG H L, SHEN W W, et al. Downregulation of CXCR4 by SDF-KDEL in SBC-5 cells inhibits their migration in vitro and organ metastasis in vivo[J]. Int J Mol Med, 2015, 35(2): 425-432. |
| [1] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 159-163. |
| [2] | LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186. |
| [3] | YU Yunliang, WANG Lili, LI Ting, FENG Jiankai. Correlations among P2RX1,prognosis and immune cells infiltration in lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 353-360,365. |
| [4] | QI Jiankao, TANG Xiao, SUN Shihui, KOU Yanfang, CUI Zhiqin. Growth inhibition of non-small cell lung cancers by Zaoci decotion in combination with cisplatin and gemcitabine [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(5): 366-372,403. |
| [5] | FENG Zhiyin, WU Yixian, HA Xiaodan, CHEN Wujin, LI Xiumei, DONG Juanjuan. Detection of p38MAPK gene in plasma cell-free DNA among patients with high incidence of esophageal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 105-109. |
| [6] | WANG Rui, LIU Ying, WU Juan, JI Xiaokun, MA Yang, GUO Xiao, DU Yun. CXCR4, Ki67, MDM2 and N-cadherin expressions in lung adenocarcinoma pleural effusion cells and their correlation with EGFR mutation status [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(2): 114-118. |
| [7] | WANG Rui, WANG Heng, WU Juan, JI Xiaokun, GUO Xiao, MA Yang, DU Yun. Values of automatic DNA image analyses in diagnosis of pancreatic malignant tumors [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 451-454. |
| [8] | ZENG Zhuoying, WU Desheng, LU Jingjing, LIAO Hui, LAI Hongpiao, YUAN Jianhui, HU Zhangli. Mediation by estrogen receptor α on oxidative phosphorylation pathways in development of lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 262-268. |
| [9] | LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295. |
| [10] | WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192. |
| [11] | DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463. |
| [12] | LIU Xiaoxia, LI Weixia, SU Zhenjun, JIA Jinhai, DUAN Xiaohui, LI Zhijia, HE Xiaolei, L Linlin, LIU Rui, WANG Yunxiao. Analyses of clinicopathological characteristics and curative effect of combined radio-with chemo-therapy for advanced non-small cell lung cancer with superoxide dismutase activity in serum [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 350-354. |
| [13] | SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373. |
| [14] | FENG Min, ABBIE·Mohetar, SHI Jingyi, ZUKELAI·Alijiang, LI Yongxiang, YAN Changshun, LI Xiumei. Expression of miR-143, miR-145 and Survivin mRNA in esophageal cancers among Kazaks [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(1): 29-32. |
| [15] | YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
